Replies to post #2200 on Endonovo Therapeutics Inc (ENDV)

[AUhills]

Great post, must read DD...

[PencilNeckGeek]

Fantastic post!!!

[136]

The company recently provided an update on its current research and development stating it expects to conduct a pre-clinical study to evaluate the effectiveness of its Immunotronics technology in accelerating the regeneration of the liver in the first quarter of 2017. It also intends to uplist its common stock onto a national stock exchange in the first half of 2017.

I am familiar with biotechs/pharma companies and these processes.

Facts are, if $ENDV 's technology works and that can be shown in this pre clinical study, this makes ENDV worth $500M-$1B (market cap)

There are two options the current market competitors have granted the results of this pre clinical study are favorable.

1. Buy $ENDV and its intellectual property for a massive premium to protect their stake in the market.

OR

2. Compete until losing that market share to $ENDV 's technology.

The big companies don't like losing...


A prime example of this type of scenario can been found by looking at a buyout that I was involved in a few years back where a very large pharmaceutical company bought a smaller one that had a new MRSA/infection fighting drug that would surely outperform the current antibiotics on the market.

http://www.fiercebiotech.com/financials/cubist-splurges-on-trius-and-optimer-buyouts-to-spur-antibiotics-growth

In simple terms, If ENDV shows positive pre clinical results (which are due by the end of this quarter 3/31/17), there will be massive interest in this company. It is all about ENDV being able to show that their electroceutical treatment works. If they can do that... the valuation will rise to unprecedented highs.

Yes, it is a risk like any stock is to be invested in. But follow the clues.

-Insider buying (Continuous even with increasing share prices)
-Uplisting to a major exchange is a priority and there are highly experienced members on the ENDV team that can make it happen.
-Bought back ~$2.2M of convertible notes

"It is very important that we buy back all outstanding convertible notes in order to prevent dilution and preserve shareholder value. We believe that our stock is considerably undervalued," continued Mr. Collier.

-Preferred financing from a strategic healthcare investor
-Intellectual Property on the technology (patents)
-Completely transparent share structure available on otcmarkets.com